Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pemigatinib in advanced malignancies (FIGHT-101)
NCT02393248Phase 2Terminated
- Sponsor
- Incyte
- Start
- Feb 2015
- Primary completion
- Dec 2021
- Modality
- Fragment-Derived Small Molecules, Reversible Covalent Inhibitors, Bivalent/Multivalent Binders
- Countries
- 2
01
Overview
A Phase 2 trial of pemigatinib in solid tumor (advanced stage), non-small cell lung cancer (NSCLC), cholangiocarcinoma (CCA), gastric cancer (GC), urothelial carcinoma (UC), sponsored by Incyte. Started Feb 2015; status: terminated.
02
Drugs
pemigatinib
03
Conditions
solid tumor (advanced stage)non-small cell lung cancer (NSCLC)cholangiocarcinoma (CCA)gastric cancer (GC)urothelial carcinoma (UC)
Beyond the preview
Go deeper on NCT02393248.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02393248.